Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say

Moderna (MRNA) reported $108 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 35.3%. EPS of -$2.52 for the same period compares to -$3.07 a year ago.The reported revenue represents a surprise of -14.95% over the Zacks Consensus Estimate of $126.98 million. With the consensus EPS estimate being -$2.92, the EPS surprise was +13.70%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product sales- United States: $31 million versus the three-analyst average estimate of $59.41 million. The reported number represents a year-over-year change of -69%. Product sales- Rest of world: $55 million versus the two-analyst average estimate of $39.60 million. The reported number represents a year-over-year change of -17.9%. Revenue- Net Product sales: $86 million compared to the $114.44 million average estimate based on eight analysts. The reported number represents a change of -48.5% year over year. Revenue- Other revenue: $22 million versus $18.43 million estimated by six analysts on average. Revenue- Other revenue- Grant revenue: $1 million versus $6.43 million estimated by three analysts on average. Revenue- Other revenue- Licensing & royalty revenue: $8 million versus $4.40 million estimated by two analysts on average. Revenue- Other revenue- Collaboration revenue: $1 million compared to the $11.25 million average estimate based on two analysts. View all Key Company Metrics for Moderna here>>>Shares of Moderna have returned +5.1% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks